A single subcutaneous injection dose, dose-escalation phase I study on the tolerability and safety of recombinant erythropoiesis stimulating proteininjection ( CHO cell ) in patients with chronic kidney disease with anaemia

Trial Profile

A single subcutaneous injection dose, dose-escalation phase I study on the tolerability and safety of recombinant erythropoiesis stimulating proteininjection ( CHO cell ) in patients with chronic kidney disease with anaemia

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jun 2016

At a glance

  • Drugs Darbepoetin alfa (Primary)
  • Indications Anaemia
  • Focus Adverse reactions
  • Sponsors 3SBio
  • Most Recent Events

    • 02 Jun 2016 Status changed from recruiting to completed.
    • 02 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top